Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00247312 · ClinicalTrials.gov registry record · Phase 3
Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial
A Phase 3 study of Prostatic Neoplasm, sponsored by Schiffler Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 319
- Enrollment target
- 2
- Study locations
NCT00247312: Completed Phase 3 study of Prostatic Neoplasm, sponsored by Schiffler Cancer Center.
NCT00247312 is a Phase 3 study of Prostatic Neoplasm that has completed, run by Schiffler Cancer Center. The registered enrollment target is 319 participants, above the 217-participant average among 9 other Prostatic Neoplasm trials with a reported enrollment target (47% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00247312, a Phase 3 study of Prostatic Neoplasm, has completed, sponsored by Schiffler Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 319 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the most appropriate radiation implant dose for palladium-103 monotherapy. Radiation dose is related to potential cure. From previously published studies, it appears that the prescribed radiation dose can be reduced by 14-20% without any difference in potential cure (in this study, the dose is being decreased 10%). Although most patients tolerate brachytherapy well, complications to appear to be related to radiation exposure to normal structures (i.e. urethra, rectum and proximal penis). By reducing the prescribed dose, it is conceivable that fewer patients will experience side effects and complications.
Conditions Studied
Interventions
- RADIATION Pd-103
Study Locations (2)
Washington
- Radiation Oncology 174 Department of Veterans Affairs - Seattle
West Virginia
- Schiffler Cancer Center - Wheeling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 319 participants |
| Start Date | 2005-10 |
| Est. Completion | 2015-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00247312
The ClinicalTrials.gov registry entry for NCT00247312 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 319 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 9 other Prostatic Neoplasm trials with a reported enrollment target (47% higher). The listed sponsor is Schiffler Cancer Center, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Pd-103 is the first listed.
NCT00247312 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Washington, West Virginia.
Frequently Asked Questions
What is clinical trial NCT00247312 about?
NCT00247312 is a clinical study titled "Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial". The purpose of this study is to determine the most appropriate radiation implant dose for palladium-103 monotherapy. Radiation dose is related to potential cure. From previously published studies, it appears that the prescribed radiation dose can be reduced by 14-20% without any difference in potent...
What is the current status of trial NCT00247312?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 319 participants. The study started on 2005-10. Estimated completion is 2015-11.
What conditions does trial NCT00247312 study?
This clinical trial studies the following conditions: Prostatic Neoplasm.
What interventions are being tested in trial NCT00247312?
The interventions under investigation include: Pd-103 (RADIATION).
Who is sponsoring clinical trial NCT00247312?
This trial is sponsored by Schiffler Cancer Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00247312 being conducted?
This trial has 2 study locations across Washington, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigation of Impact of AI on Prostate Cancer Workflow
RECRUITING · NA
-
Prostate Cancer Genetic Risk Evaluation and Screening Study
RECRUITING
-
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
ACTIVE NOT RECRUITING · Phase 2
-
Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness
ACTIVE NOT RECRUITING · Phase 1
-
Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors
COMPLETED · NA
-
I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).
COMPLETED · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.